The Phase III IMforte study shows that adding lurbinectedin to Tecentriq for ES-SCLC first-line maintenance reduced disease ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

Prof Patrick Forde of the Trinity St James’s Cancer Institute presented the findings at the latest meeting of the American ...

The American Cancer Society says more people are surviving cancer, and a new study estimates there are 18.6 million people in the U.S. living with a history of cancer as of Jan 1. By the year 2035, ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy ...

The Turquoise Takeover that spanned New Jersey from May 5-11 shined a spotlight on lung cancer awareness. Known as Lung ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...